13
total announcements
544529.BO · 15 min delayed
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the closure of its trading window under the Insider Trading Code, effective from October 1, 2026, until the completion of 48 hours after the declaration of its half-yearly financial results for September 30, 2026.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the results of its 16th Annual General Meeting (AGM) held on September 14, 2026, along with the Scrutinizer's Report. The meeting saw a total of 13,938,000 votes cast, with all three resolutions passed unanimously.
Aptus Pharma Ltd
Aptus Pharma Ltd held its 16th Annual General Meeting (AGM) on September 14, 2026, through video conferencing. The meeting was attended by 28 members, and the requisite quorum was present throughout. The company's statutory auditors, secretarial auditor, and scrutinizer were also present. The meeting was conducted in compliance with applicable provisions of the Companies Act, 2013, and SEBI Listing Regulations.
Aptus Pharma Ltd
Aptus Pharma Ltd has submitted a newspaper advertisement for the Corrigendum to the Notice of the 16th Annual General Meeting, which was published in The Indian Express and Financial Express.
Aptus Pharma Ltd
Aptus Pharma Ltd announces its next growth phase with focus on manufacturing, pan-India expansion, and global markets. The company plans to raise ₹44.88 crore through a preferential issue of equity shares and utilize the funds for capital expenditure, working-capital requirements, and general corporate purposes.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced an investor presentation under Regulation 30 of SEBI (LODR) Regulations, 2015, for the year ended 31st March, 2026, which includes financial results and a company overview.
Aptus Pharma Ltd
Aptus Pharma Ltd has submitted its Annual Report for FY 2025-26, including the Notice of Annual General Meeting, Directors Report, Independent Auditors Report, and Audited Financial Statements.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced its 16th Annual General Meeting (AGM) to be held on September 14, 2026, through video conferencing. The meeting will consider the adoption of financial statements, appointment of a director, and approval of a preferential allotment of equity shares.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the outcome of its board meeting, where it considered and approved the final number of allottees and the number of equity shares to be issued on a preferential basis. The company also determined and approved the issue price for the proposed preferential issue of 16,02,870 equity shares, based on the valuation report obtained from the Registered Valuer.
Aptus Pharma Ltd
Aptus Pharma Ltd has informed BSE that a meeting of the Board of Directors is scheduled on August 17, 2026, to consider and approve prior intimation of the board meeting, including the valuation report for a preferential issue, determination of issue price, and convening of the 16th Annual General Meeting.
Aptus Pharma Ltd
Aptus Pharma Ltd has issued a clarification regarding typographical errors in its board meeting outcome announcement, stating that the errors are purely typographical and do not change the substance or outcome of the resolutions passed.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the outcome of its board meeting, where it approved the preferential issue of 16,10,100 equity shares at a price to be determined by a registered valuer. The company also fixed the date of its annual general meeting for September 14, 2026. The preferential issue is subject to the approval of the shareholders and other necessary approvals.
Aptus Pharma Ltd
Aptus Pharma Ltd has informed BSE that a Board Meeting is scheduled on August 8, 2026, to consider raising funds through a preferential allotment of equity shares and to announce the closure of the trading window.